Welcome to our dedicated page for Belite Bio SEC filings (Ticker: BLTE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Belite Bio’s SEC filings explained simply—yet they’re anything but simple. Clinical trial endpoints, FDA designations and cash-runway calculations crowd every report, turning a standard 10-K into a dense scientific dossier. If you have ever wondered where to find Belite Bio quarterly earnings report 10-Q filing notes on R&D spend or how to track Belite Bio insider trading Form 4 transactions, you know the challenge.
Stock Titan’s AI-powered analysis solves this in seconds. Our engine parses each disclosure the moment it hits EDGAR, flags pivotal data and serves it back in plain language. No more hunting for the single paragraph that details Phase 3 enrollment; ask in natural English—“understanding Belite Bio SEC documents with AI”—and get the answer instantly.
- Belite Bio annual report 10-K simplified—AI spotlights trial progress, patent updates and dilution risk.
- Belite Bio 8-K material events explained—read concise summaries of FDA feedback or orphan-drug status changes.
- Belite Bio proxy statement executive compensation—see how incentives align with clinical milestones.
- Belite Bio Form 4 insider transactions real-time—receive alerts on director buys or sells within minutes.
Whether you need Belite Bio earnings report filing analysis for your cash-runway model or want to monitor Belite Bio executive stock transactions Form 4 before key data releases, our comprehensive coverage and expert commentary keep you ahead. Complex biotech filings become clear, actionable insights—so you can focus on decisions, not document mining.
Form 144 filing for Belite Bio, Inc. (BLTE) reports a proposed sale of 30,000 American Depositary Shares (each representing one ordinary share) through J.P. Morgan Securities LLC on NASDAQ with an aggregate market value of $1,902,600 and an approximate sale date of 08/21/2025. The filer acquired the 30,000 ADS on 03/07/2025 by exercising stock options and paid cash on that date. The filer states there were no securities sold in the past three months attributable to the same person, and the notice includes the standard Rule 144 representation about lack of undisclosed material information.
Belite Bio (Nasdaq: BLTE) filed a 424B5 to raise capital via a direct, best-efforts placement of 230,770 ADSs (1 ADS = 1 ordinary share) at $65.00 each, bundled one-for-one with five-year warrants exercisable at the same price. Gross proceeds total $15.0 million; the placement-agent fee is 6.5% ($0.975 m), leaving $14.0 m before other expenses. Proceeds are earmarked for working capital and general corporate purposes.
Post-offering share count rises to 32.83 m (33.06 m fully diluted). Warrants are immediately exercisable, unlisted, and capped at 9.99% beneficial ownership. Company lock-ups: 30 days (issuer) and 60 days (insiders & ≥5% holder). Closing is expected on 8 Aug 2025; Titan Partners Group acts as exclusive placement agent.
Risks disclosed include continued cash burn, reliance on lead drug Tinlarebant, potential PRC regulatory exposure despite limited China operations, likely PFIC status, dilution (immediate book-value drop of $59.75/ADS) and controlled-company governance exemptions. Last BLTE close (6 Aug 2025) was $67.99, implying a modest 4.4% discount. No change to Nasdaq listing of ADSs; warrants will not be listed.
FAQ
What is the current stock price of Belite Bio (BLTE)?
What is the market cap of Belite Bio (BLTE)?
